News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TipRanks Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Adagio Medical has released an updated investor presentation detailing its ULTA technology and clinical program. Key highlights include the full enrollment of the FULCRUM‑VT pivotal trial, projected FDA PMA approval for its first-gen vCLAS in Q4 2026, and $7.7 million in cash as of …
This article announces that Adagio Medical Holdings Inc. has filed a Form 8K for August 11. The filing is related to the company's financial activities and is reported by Investing.com.
Adagio Medical reported a net loss of $6.7 million for Q2 2026 with no revenue, and ended the quarter with $7.7 million in cash. The company highlighted positive results from its FULCRUM-VT trial and the first patient treatment with its next-generation vCLAS Ultra catheter, …
Adagio Medical Holdings, Inc. reported its 2026 quarterly results, with revenue reaching $4.93M and a diluted loss per share of ($0.3). The company announced significant business highlights, including completing enrollment for the FULCRUM-VT pivotal IDE study, submitting a PMA for vCLAS, and launching the …
This document provides a company profile and introduction for Adagio Medical. It outlines the company's background, key operations, and overall business focus, serving as a foundational overview for understanding its market position and strategic direction.
Adagio Medical (NASDAQ: ADGM) shares climbed 22% in after-hours trading after the company announced the successful treatment of the first patient with its next-generation vCLAS Ultra ablation system under FDA Expanded Access. The new system aims to treat abnormal heart rhythms without open-heart surgery, …
Adagio Medical has successfully treated the first patient with its next-generation vCLAS Ultra Ultra-Low Temperature Ablation (ULTA) system under FDA Expanded Access. The new system aims to optimize usability and reduce procedure time for ventricular tachycardia (VT) patients, building on the proven safety and …
Adagio Medical has successfully treated its first patient with the next-generation vCLAS Ultra-Low Temperature Ablation system under FDA Expanded Access. This advanced system, designed for greater maneuverability and faster procedures, addresses ventricular tachycardia that has resisted other treatments, particularly in difficult-to-reach areas near critical …
This article details
Sio Capital Management, LLC has reported a decrease in its beneficial ownership of Adagio Medical Holdings, Inc. (ADGM) common stock to 3.15%, or 698,989 shares, as of June 30, 2026. This position is below the 5% threshold for passive investment disclosure, with Sio Capital …
This article provides an overview of Adagio Medical Holdings Inc (ADGM), including its current stock price and market capitalization. It highlights that revenue breakdown data by business and region has not yet been disclosed by the company. The page also mentions Finsights' role in …
This article provides a detailed cash flow statement for Adagio Medical Holdings Inc (ADGM), covering quarterly data for operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and ADGM's performance in these areas, such as its …
This article provides an overview of Adagio Medical Holdings Inc (ADGM) focusing on its dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts. The page also presents current …
The article provides a revenue breakdown for Adagio Medical Holdings, Inc (NASDAQ: ADGM) based on data from TradingView. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segment performance. The content is primarily a data placeholder and navigational information …
Adagio Medical Holdings Inc (ADGM) has strong fundamentals and high growth potential, despite a recent weak stock market performance. Its valuation is considered fairly priced, with institutional ownership being very high. Analysts have rated it as a Buy, with a target price suggesting a …
This article provides an analysis of Adagio Medical Holdings Inc's (ADGM) financial health, ranking it 143 out of 200 in the Healthcare Equipment & Supplies industry with a current financial score of 6.66. While its financial status is robust, the operating efficiency is low. …
This article provides a detailed quarterly income statement for Adagio Medical Holdings Inc (ADGM) from FY2021Q4 to FY2026Q1, including key financial metrics like total revenue, operating expenses, net income, and basic/diluted earnings per share. It also includes FAQs explaining how to interpret income statements …
This article assesses the risk profile of Adagio Medical Holdings Inc (ADGM), noting its current risk score of 1.46, placing it 182nd out of 200 in the Healthcare Equipment & Supplies industry. The company's beta of -0.18 indicates it tends to underperform in bull …
This article provides an analysis of Adagio Medical Holdings, Inc.'s interest coverage ratio. The company's interest coverage was -7.5x in FY2025 and -6.5x on a trailing-twelve-month basis as of Q1 FY26, indicating that its operating income does not cover its interest expenses. The data …
Search by ticker symbol or company name and select a result to open its chart.